On this page
What it is
A tripeptide of glutamate, cysteine and glycine, present in every cell and central to redox balance and detoxification. Not a research peptide in any meaningful sense — it is basic biochemistry, sold as a product.
How it is proposed to work
As an antioxidant and cofactor it is genuinely essential. The leap is from 'essential' to 'more is better when injected', which does not follow: levels are homeostatically regulated, and oral glutathione is extensively broken down before absorption.
Approved medical uses
Used medically in some countries in specific contexts, including as an adjunct in certain chemotherapy protocols. Those uses are narrow, supervised, and unrelated to wellness infusion.
Human research
Each entry states what the study found and, separately, what it cannot show.
- Randomised controlled trial1995n = 50
Reduced glutathione and cisplatin-induced neuropathy in advanced gastric cancer
Finding. A randomised double-blind placebo-controlled trial in patients with advanced gastric cancer on a weekly cisplatin-based regimen, testing glutathione given around each cisplatin administration for prevention of cisplatin-induced neurotoxicity. At the 9th week no patients showed clinically evident neuropathy in the glutathione arm, against 16 patients in the placebo arm; after the 15th week four of 24 assessable patients in the glutathione arm had neurotoxicity versus 16 of 18 in the placebo arm (P = .0001). Median, ulnar and sural sensory nerve conduction fell significantly in the placebo arm but not in the glutathione arm, most clearly in potential amplitude. Response rate, a secondary comparison reported without a significance test, was 76% (20% complete) with glutathione and 52% (12% complete) with placebo, which the authors read as glutathione not reducing the activity of the cytotoxic drugs.
Limitation. A narrow supervised oncology setting: glutathione was given by infusion immediately before each cisplatin dose and by injection on the following days, in advanced gastric cancer, as neuroprotection during chemotherapy. Fifty patients were enrolled, but by the 15th week the comparison rested on 24 patients in the glutathione arm and 18 in the placebo arm, a smaller group than the enrolled total. Nothing here speaks to glutathione infused for skin lightening or general wellness.
Preclinical research
Animal and laboratory work. Useful for generating hypotheses; it cannot establish that something works in people.
No preclinical studies catalogued.
Potential safety concerns
- SeriousPromising
Injectable glutathione for skin lightening has drawn public safety warnings from national regulators in the region where it is most heavily marketed, citing serious adverse events. This is a documented regulatory position, not a theoretical concern.
- SeriousEstablished
Intravenous administration in non-clinical settings carries the infusion risks common to all such practice: sterility failure, anaphylaxis, and no monitoring when something goes wrong.
- CautionEstablished
Skin lightening as a goal sits in an industry with a documented record of unsafe products. That context is part of the risk picture.
Known interactions and contraindication considerations
- Relevant in oncology settings, where antioxidant supplementation during treatment is a genuine clinical question.
This list is not exhaustive and is not a substitute for a clinician reviewing your full medication history.
Regulatory status
Status is shown per jurisdiction and is accurate only as of the date stated. Where a compound is approved, the approval is bound to a specific formulation, manufacturer and indication — shown in the detail column.
| Jurisdiction | Standing | Detail |
|---|---|---|
United States FDA | Not approved as of 11 Aug 2026 | Not approved for injection or infusion for skin lightening or general wellness. Compounded injectable products in this category have drawn regulatory attention. |
European Union EMA | Not approved as of 11 Aug 2026 | No authorisation for these uses. |
India CDSCO | Restricted as of 11 Aug 2026 | Injectable use for skin lightening is widely marketed across South and South-East Asia and has attracted regulatory warnings in the region. Confirm current CDSCO position before relying on this. |
How it is being used
What the grey community actually runs, the reasoning they give, and our read on whether it follows from known biology. This is observation, not evidence, and not a recommendation.
No community use documented for this compound yet. Absence here means our editorial team has not reviewed and verified a pattern — not that none exists.
Active clinical trials
No registered trials currently tracked for Glutathione.
What remains unknown
The questions that would change our assessment if they were answered.
- Does raising systemic glutathione produce any outcome a person notices?
- Is the skin-lightening effect real, and if so through what mechanism?
References
Editorial change history
When we change a grade or a regulatory note, we log it here rather than editing quietly.
Dossier created. Two specific harm statistics were excluded as uncited despite being offered as the justification for the grade; the grade rests instead on documented regulatory warnings.
Spotted something wrong? Tell us — we publish corrections.